{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one AE was assessed.","groups":[{"description":"Adult participants received pembrolizumab (MK-3475) 200 mg or pediatric participants received 2 mg/kg (up to 200 mg) on Day 1 Q3W IV for up to 35 administrations (approximately 2 years).","id":"OG000","title":"Pembrolizumab 200 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis population consisted of all allocated participants who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to ~58 months","title":"Number of Participants With One or More Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"Participants"}